Literature DB >> 28837971

Mortality and its Causes in a German Cohort with Diabetes Mellitus Type 1 after 20 Years of Follow-Up: The JEVIN Trial.

Tabitha Heller1, Christof Kloos1, Thomas Lehmann2, Ralf Schiel3, Stefan Lorkowski4,5, Gunter Wolf6, Ulrich Alfons Müller1, Nicolle Müller1.   

Abstract

BACKGROUND: The JEVIN trial started as a cross-sectional study in 1989/90 in Jena. After a follow-up of more than 20 years, the mortality incidence of JEVIN participants with type 1 diabetes was surveyed.
METHODS: 103 (78.6%) of the 131 JEVIN patients participating at baseline could be examined. 38 persons (36.9%) had deceased. All JEVIN survey data and routine examinations documented in the electronic patient record EMIL® of surviving and deceased participants were used for analyses. We compared the data of the surviving with the deceased participants (follow-up time: 2,166 person-years).
RESULTS: The incidence rate of death was 1.75/100 person-years. Median observation time for all patients was 23.1 years (range 0.61-26.6 years). Mean age at death was 58.5 years (34.2-78.4 years), and diabetes duration 35 years (3.5-68.5 years). Most frequent causes of death were: cardiovascular diseases (48.2%, n=13) and infections (25.9%, n=7). There were no differences in age (p=0.302), diabetes duration (p=0.371), BMI (p=0.535), blood pressure (p=0.622/0.820), gender (p=0.566), and smoking status (p=0.709) between surviving and deceased persons. The mean HbA1c of the last year before death or last visit was higher in the deceased than surviving persons (7.5% vs. 7.0%; p=0.010). 57.4% of the surviving and 87.0% of the deceased participants had nephropathy (p=0.012), 79.7% vs. 89.7% retinopathy (p=0.241) and 61.4% vs. 63.3% neuropathy (p=0.860), but only nephropathy was significantly associated with increased mortality risk (HR=4.208, CI:1.226-14.440; HR=2.360, CI:0.696-8.004; HR=0.944, CI:0.436-2.043).
CONCLUSIONS: In the JEVIN population with diabetes mellitus type 1 only, diabetic nephropathy was associated with higher mortality risk. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2017        PMID: 28837971     DOI: 10.1055/s-0043-113452

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  4 in total

Review 1.  Remodeling of Retinal Architecture in Diabetic Retinopathy: Disruption of Ocular Physiology and Visual Functions by Inflammatory Gene Products and Pyroptosis.

Authors:  Rubens P Homme; Mahavir Singh; Avisek Majumder; Akash K George; Kavya Nair; Harpal S Sandhu; Neetu Tyagi; David Lominadze; Suresh C Tyagi
Journal:  Front Physiol       Date:  2018-09-05       Impact factor: 4.566

2.  Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study.

Authors:  Monia Garofolo; Elisa Gualdani; Rosa Giannarelli; Michele Aragona; Fabrizio Campi; Daniela Lucchesi; Giuseppe Daniele; Roberto Miccoli; Paolo Francesconi; Stefano Del Prato; Giuseppe Penno
Journal:  Cardiovasc Diabetol       Date:  2019-11-16       Impact factor: 9.951

3.  Illness-Death Model in Chronic Disease Epidemiology: Characteristics of a Related, Differential Equation and an Inverse Problem.

Authors:  Ralph Brinks
Journal:  Comput Math Methods Med       Date:  2018-09-12       Impact factor: 2.238

4.  Diabetic retinopathy predicts cardiovascular mortality in diabetes: a meta-analysis.

Authors:  Xiao-Hong Xu; Bo Sun; Shan Zhong; Dong-Dong Wei; Ze Hong; Ai-Qiang Dong
Journal:  BMC Cardiovasc Disord       Date:  2020-11-04       Impact factor: 2.298

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.